News - Xgeva

Filter

Current filters:

Xgeva

Popular Filters

FDA backs Amgen's Xgeva for new use, to treat giant cell tumor of the bone

14-06-2013

The US Food and Drug Administration late yesterday (June 13) expanded the approved use of biotech major…

AmgenBiotechnologyNorth AmericaOncologyRegulationXgeva

Amgen's Xgeva gets NICE backing for bone metastasis

24-10-2012

New guidance published today (October 24) by the UK's drugs watchdog the National Institute for Health…

AmgenBiotechnologyEuropeOncologyPricingRegulationXgeva

Denosumab reduces burden of giant-cell tumor of the bone

25-09-2012

Treatment with denosumab, a drug from Amgen (Nasdaq: AMGN), the world's largest biotech firm which markets…

AmgenBiotechnologydenosumabOncologyProliaResearchXgeva

UK's NICE continues to back Amgen's Xgeva for most cancer patients with bone metastases

17-08-2012

In a final draft guidance issued today, (August 17), the National Institute for Health and Clinical Excellence…

AmgenBiotechnologyEuropePricingRegulationXgeva

UK's NICE takes second look at Amgen's Xgeva

12-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) today launched a second…

AmgenBiotechnologyEuropeOncologyPricingRegulationXgeva

FDA stalls Amgen's Xgeva sBLA for prevention of bone metastases

30-04-2012

USA-based Amgen (Nasdaq: AMGN) revealed on Friday that the US Food and Drug Administration has issued…

AmgenBiotechnologyNorth AmericaOncologyRegulationXgeva

NICE recommendations on Bayer's Xarelto and Amgen Xgeva's for UK NHS use

30-03-2012

Following the receipt of further evidence from Bayer HealthCare, a unit of German drugmaker Bayer (BAY:…

AmgenBayerCardio-vascularEuropeOncologyPharmaceuticalPricingRegulationXareltoXgeva

Four new drugs will change prostate cancer care, says US expert

19-02-2012

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer…

AlgetaAlpharadinAmgenBavarian NordicBayerJohnson & JohnsonOncologyPharmaceuticalProstvacXgevaZytiga

Amgen fails to get FDA advisory backing for extended use of Xgeva

09-02-2012

The world’s largest independent biotech firm, Amgen (Nasdaq: AMGN), has failed to convince a Food…

AmgenBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationXgeva

Global osteoporosis market report sees strong showing in China

01-02-2012

The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and…

AmgenAnti-Arthritics/RheumaticsAsia-PacificGlobalMarkets & MarketingPharmaceuticalXgeva

More cancer and HIV drugs added to Australian PBS

07-12-2011

More than 160,000 patients will benefit directly from changes to Australia’s Pharmaceutical Benefits…

AmgenAnti-viralsAsia-PacificGilead SciencesOncologyPharmaceuticalPrezistaPricingRegulationXgeva

Regulatory updates for Incivek, Xgeva and Corlux in North America

23-08-2011

In a batch of regulatory news released yesterday, Vertex Pharmaceuticals (Nasdaq: VRTX) said that Health…

AmgenAnti-viralsCorcept TherapeuticsCorluxIncivekNorth AmericaPharmaceuticalRare diseasesRegulationVertexXgeva

Back to top